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Letter to the EditorDelayed-onset adenosine deaminase defi-
ciency: Strategies for an early diagnosis
To the Editor:
Adenosine deaminase (ADA) deficiency is a well-known cause
for severe combined immunodeficiency (SCID). However,
hypomorphic mutations in the ADA gene can lead to a different
immunodeficiency with variable phenotype including signs of im-
mune dysregulation.1,2 Early diagnosis and therapeutic manage-
ment often remain a challenge. We report on 2 ADA-deficient
patients with delayed-onset (P1) and late-onset1 phenotype (P2)
illustrating these difficulties and describe how newborn screening
could have facilitated early diagnosis in one of these patients.
The clinical and laboratory findings of our patients are sum-
marized in Table I. Chronic lymphopenia and elevated IgE levels
were key findings in routine laboratory investigations. Further
analysis of lymphocyte subsets identified a T(1)BlowNKlow phe-
notype. The T-cell receptor repertoire was diverse.
The presence of autoimmune phenomena (Table I) in the context
of panlymphopenia prompted us to determine ADA levels3 that
were undetectable in dried blood spot punches. Correspondingly,
total adenine deoxyribonucleotides levels were elevated. Subse-
quent sequencing of the ADA gene revealed compound heterozy-
gous mutations in P1 and P2. Both patients carried the same
intron 8 splice donor site mutation (c.78011G>A), while the sec-
ondmutationwas c.637G>T (predicting a novelVal213Phe substi-
tution in exon 7) in P1 and c.396dupA (p.Val133SerfsX38) in P2.
Expression of a cDNA encoding the V213F mutation in an Esche-
richia coli system yielded about 1% of wild-type ADA activity,
classifying it as a ‘‘group III allele,’’ which is in line with missense
mutations found in previous late-onset ADA-deficient patients.1
While P1 was lost to follow-up after diagnosis, we initiated
enzyme replacement therapy (ERT) in P2. He achieved immune
reconstitution within 4 weeks as determined by the normalization
of cell numbers, T-cell proliferation, and pneumococcal vaccine
responses. A marked drop in ADA activity 3 months later (Fig 1)
was due to the presence of neutralizing antibodies. An increase in
the polyethylene glycol–modified ADA dose resulted in sustained
normalization ofADAactivity and continuous systemic detoxifica-
tion. The chronic cough of P2 cleared within weeks after the initi-
ation of ERT, and former radiological signs of interstitial alveolitis
resolved completely as found in a recent computed tomography
scan. Improvement in pulmonary symptoms correlated with the
level of detoxification rather than with the later occurring immune
reconstitution, in line with previous reported observations.4
The clinical course of our patients and other individuals
summarized in Felgentreff et al2 clearly demonstrate that patients
with delayed-onset and late-onset ADA deficiency suffer signifi-
cantly from the damaging consequences of their disease. Those
diagnosed as adults showed severe chronic lung disease and other
serious health problems and have not survived long after diagno-
sis.5,6While ERT is a generally accepted treatment in ADA-SCID
to stabilize patients prior to stem cell transplantation, its use in pa-
tients with a later onset of the disease is less well documented.7
Although initial immune reconstitution can be observed in most
patients receiving ERT, several develop neutralizing antibodies
against the bovine-derived ADA, which can completely reverse
immune recovery.8 Fortunately, in P2 and other patients, it hasbeen possible to overcome this problem by increasing the
dose.9 In 2 adult sisters,6 immune recovery was minimal under
ERTand one of them died because of chronic lung disease. How-
ever, more favorable results have been reported in other patients.7
The data from P2 are encouraging, also regarding the lung disease
observed in some ADA-deficient patients.4 We believe that ERT
also has an important role in patients diagnosed beyond infancy,
mainly to prevent the development of comorbidities that increase
the risk for stem cell transplantation.
Since therapeutic success relies on the early initiation of
treatment prior to the occurrence of chronic organ damage, we
addressed the question whether the diagnosis of late-onset ADA
deficiency couldbe facilitatedbyusingnewborn screeningmethods
recently introduced for SCID.10We therefore obtained dried blood
spot punches from the original Guthrie card from P2. Copy num-
bers of T-cell receptor excision circles (TRECs) repeatedly proved
to bewithin normal limits at birth, even though lymphopenia (1288/
mL) was already documented at age 2 months. ADA deficiency
would have therefore been missed in P2 by currently established
population-based newborn screenings for SCID, which are based
on TREC analysis.10 Notably, the analysis of dried blood spot
punches revealed markedly reduced copy numbers of kappa-
deleting recombination excision circles (KRECs)—despite the
patient’s later documented ability toproduce a significant repertoire
of specific antibodies. In a screening setting, the phenotype of P2
with normal TRECs and reduced KRECs would have rather pre-
dicted a B-cell and not a T-cell deficiency.11 In addition, we also
performed tandemmass spectrometry for the detection of elevated
adenosine metabolites12 and identified that increased levels of des-
oxiadenosine and adenosine were already present at birth.
Our data indicate that late-onset ADA deficiency may be
missed when screening is based on TREC analysis only. In our
patient, KREC analysis was more helpful, indicating that de-
creased KREC copy numbers at birth should also raise suspicion
of combined immunodeficiencies. Notably, mass spectrometry
showed markedly increased desoxiadenosine and adenosine
levels, indicating that this technique may also be useful in
newborn screening to identify leaky ADA variants, particularly
since spectrometry can be performed at a negligible cost.12 Pro-
spective analysis in ongoing screening programs will be neces-
sary to prove this hypothesis. It must be considered, however,
that screening will also identify patients with partial ADA defi-
ciency,1 who will not develop symptoms of immunodeficiency
and do not require treatment. Determination of lymphocyte
counts, total adenine deoxyribonucleotides in red blood cells,
and genetic analysis will be helpful in evaluating the individual
prognosis, since there is a strong correlation between ADA gen-
otype and both metabolic and clinical phenotype.1
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TABLE I. Clinical phenoype and laboratory investigations in P1 and P2
Clinical phenotype P1 P2
Ethnicity Caucasian Caucasian
Autoimmunity AIHA, eczema, asthma, colitis Asthma
Intensity of autoimmunnity Severe (AIHA) Moderate
Onset of autoimmunity (y) 6 4
Infection profile Sinopulmonary Otitis, pulmonary
Intensity of infections Severe Moderate
Onset of infections (y) 3 3
Radiological findings Bronchiectasis Alveolitis
Treatment CSA, steroids, SCIG, antibiotics ERT
Age at diagnosis (y) 21 (late-onset as defined in Arredondo-Vega et al1) 7 (delayed-onset as defined in Arredondo-Vega et al1)
P1 P2 Normal range
Laboratory investigations
Lymphocytes/mL <500 900 1000-5300
Eosinophils (% of leucocytes) 24 8 5
T cells
CD31/mL 236 880 800-3500
CD41/mL 110 156 300-1400
CD81/mL 154 574 200-900
%gamma/delta TCR1CD31 <10 59 <10
%CD45RA of CD41 9.7 44 48-68
B cells
CD191/mL 6 13 100-500
Natural killer cells
CD3-CD161CD561/mL 17 20 90-600
Immunoglobulins
IgG (g/L) (prior SCIG) 10.8 7.8 7-16
IgA (g/L) 0.95 0.41 0.7-4
IgM (g/L) 0.23 0.27 0.4-2.3
IgE (kU/L) 11,200 204 <100
Specific IgG 1Tetanus 1hb, tetanus, hib, measles, mumps 1
2Measles 2Diptheria, pertussis, rubella, 1
Isohemagglutinins 1 2 1
Autoantibodies RBCs, neutrophils PEG-ADA 1
Proliferation
PHA Low* Low/normal after ERT
Anti-CD3/CD28 Low* Low/normal after ERT
Tetanus Low* ND
ADA mutation c.637G>T c.396dupA
(p.Val213Phe) (p.Val133SerfsX38)
c.78011G>A c.78011G>A
ADA activity (at time of diagnosis)
In DBSS (mmol/h/mg protein) 0 0 26.4 6 10
In erythrocytes (IU/L erythrocytes) <20 111 250-650
RBC nucleotides %dAXP 6.9 7.1 <1
Analysis of newborn DBSS
TRECs (mL dried blood)11 NA 98 >15
KRECs (mL dried blood)11 NA 1.3 >10
Desoxyadenosine (mM)12 NA 0.7 <0.07
Adenosine (mM)12 NA 10 <1.5
Nucleotide numbering according to reference NM_000022.
AIHA, Autoimmune hemolytic anemia; CSA, cyclosporine A; dAXP, total adenine deoxyribonucleotides; DBSS, dried blood spot punches; hb, hepatitis B; hib, Haemophilus
influenzae; NA, not available; ND, not determined; PEG-ADA, polyethylene glycol-modified adenosine deaminase; RBCs, red blood cells; SCIG, subcutaneous immunoglobulin
substitution; TCR, T-cell receptor.
*Determined by thymidine incorporation assay.
Determined by carboxyfluorescein diacetate succinimidylester (CFSE) proliferation assay.
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FIG 1. The course of lymphocyte subsets in relation to enzyme activity andmetabolites in P2. Top panel: the
course of lymphocyte subsets determined by flow cytometry before and after the initiation of ERT. Black line
indicates CD41 cells, spotted gray line CD81 cells, gray line CD191 cells, and gray dashed line CD16/561
cells. Bottom panel: ADA activity (black dashed line) and total adenine deoxyribonucleotides (dAXP) levels
(gray line) as determined by the analysis of dried blood spots from the time point of diagnosis (210) until 54
weeks after the initiation of ERT with polyethylene glycol–modified adenosine deaminase. ‘‘0’’ indicates the
time point when ERT was started. The dose was increased at week 18 as indicated.
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